As many as 30 patients with early stage prostate cancer could be treated with a new, minimally-invasive device in a clinical trial expected to begin at two U.S. hospitals later this year, says Paul Chipperton, CEO of Profound Medical, Inc. (PMI).

The trial will evaluate the safety and effectiveness of the company's innovative MR-guided thermal ultrasound device, which Chipperton says has the potential to treat patients three to six times faster with greater accuracy and fewer side effects than existing options. Click here to view video and read full report.

The Focused Ultrasound Foundation Newsletter

Our newsletter delivers updates for clinicians, researchers and patients. Sign up and stay on top of the rapid advancements of this innovative medical technology.

Sign Up  Read the Latest Issue

Read The Tumor  by John Grisham

From John Grisham, comes a story where today’s medical fiction could become tomorrow’s lifesaving reality.

Download a Free eBook or Audiobook

Contact Details

Call Us
434.220.4993
Find Us
Focused Ultrasound Foundation
1230 Cedars Court, Suite 206 Charlottesville, VA 22903
Email